IQVIA Holdings, Inc. Common Stock (IQV)

Date: February 12, 2026 Introduction ICON plc (NASDAQ: ICLR) currently finds itself at a pivotal and precarious crossroads. As the world’s second-largest Clinical Research Organization (CRO), the Dublin-headquartered giant has long been the backbone of global drug development, orchestrating the complex trials that bring life-saving therapies to market. However, as of February 2026, the company [...]

IQVIA’s fourth quarter was marked by solid top-line growth, surpassing Wall Street’s revenue expectations. However, the market reacted negatively, focusing on margin compression and concerns about the sustainability of recent gains. Management attributed the quarter’s performance to continued investments in clinical and commercial offerings, expansion of Phase I trial capabilities, and strong demand for its data-as-a-service solutions. CEO Ari Bousbib acknowledged that a challenging macroeconomic environment and slower customer decision-making, particularly in biotech, weighed on earlier results, while improved demand indicators became evident as the year progressed.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world’s largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enhance the conduct of clinical research in obesity and related cardiometabolic trials.

Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.

IQVIA (IQV) Q4 2025 Earnings Call Transcript

Shares of clinical research company IQVIA (NYSE: IQV) fell 8.5% in the morning session after the company issued a weak full-year 2026 profit forecast that fell below Wall Street expectations. 

Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025.

Clinical research company IQVIA (NYSE: IQV) will be reporting results this Thursday before market hours. Here’s what you need to know.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey.

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2026 Fortune® World’s Most Admired Companies™ list.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

What a time it’s been for IQVIA. In the past six months alone, the company’s stock price has increased by a massive 51.4%, reaching $242.50 per share. This performance may have investors wondering how to approach the situation.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.